The Food and Drug Administration today released a briefing document on Pfizer’s BNT162b2 COVID-19 vaccine candidate that confirms the drug maker’s claims of the vaccine’s efficacy and safety. The document is among a host of materials released in advance of the key Dec. 10 meeting of FDA’s vaccine advisory committee in which Pfizer’s request for an emergency use authorization for BNT162b2 will be considered. FDA mirrored Pfizer’s application in its findings, stating that there are no specific safety concerns across key categories of race, age, ethnicity, medical co-morbidities or prior COVID-19 infection.

However, the agency notes that more data is needed to understand the vaccine’s efficacy against asymptomatic infection, which FDA says is possibly lower than its effectiveness against symptomatic infection. FDA also would like to see additional testing on the vaccine’s effectiveness in preventing the virus’ transmission.

Related News Articles

Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…